2剂BNT162b2(辉瑞BioNTech)mRNA疫苗在5-11岁儿童和12-15岁青少年中预防SARS-CoV-2感染的有效性——PROTECT队列,2021年7月至2022年2月
CDC免疫实践咨询委员会分别于2021年5月12日和2021年11月2日推荐BNT162b2疫苗用于12-15岁青少年和5-11岁儿童。PROTECT前瞻性队列纳入1,364名5-15岁儿童和青少年,于2021年7月25日至2022年2月12日每周检测SARS-CoV-2。完成2剂BNT162b2后14-82天,5-11岁儿童对Omicron感染(有症状和无症状)的调整疫苗有效性为31%(95%CI=9%-48%);12-15岁青少年接种2剂后14-149天对Delta感染的调整疫苗有效性为87%(95%CI=49%-97%),对Omicron感染为59%(95%CI=22%-79%)。
要点
- 5-11岁儿童接种2剂BNT162b2后14-82天对Omicron感染的疫苗有效性为31%(95%CI=9%-48%)。
- 12-15岁青少年接种2剂后14-149天对Delta感染有效性87%(95%CI=49%-97%),对Omicron感染59%(95%CI=22%-79%)。
- 未接种者中Delta感染报告COVID-19症状的比例(66%)高于Omicron感染(49%)。
核心结论
- 所有符合条件儿童和青少年应按照推荐保持COVID-19疫苗接种最新状态。
研究设计与样本
- PROTECT前瞻性队列纳入1,364名5-15岁儿童和青少年,于2021年7月25日至2022年2月12日每周检测SARS-CoV-2,不论有无症状,并在COVID-19相关疾病发生时检测。
主要发现
- 未接种 participant 中,Delta感染报告COVID-19症状的比例为66%,Omicron感染为49%。
- 5-11岁儿童完成2剂BNT162b2后14-82天,对Omicron感染(有症状和无症状)的调整疫苗有效性为31%(95%CI=9%-48%)。
- 12-15岁青少年完成2剂后14-149天,对Delta感染(有症状和无症状)的调整疫苗有效性为87%(95%CI=49%-97%),对Omicron感染为59%(95%CI=22%-79%)。
- 完成接种的Omicron感染者平均卧床病假时间比未接种Omicron感染者少半天。
关键数值与推荐
- CDC免疫实践咨询委员会于2021年5月12日推荐BNT162b2疫苗用于12-15岁青少年。
- CDC免疫实践咨询委员会于2021年11月2日推荐BNT162b2疫苗用于5-11岁儿童。
临床怎么用
- 所有符合条件儿童和青少年应按照推荐保持COVID-19疫苗接种最新状态。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for persons aged 12-15 years (referred to as adolescents in this report) on May 12, 2021, and for children aged 5-11 years on November 2, 2021 (1-4). Real-world data on vaccine effectiveness (VE) in these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant in the United States in December 2021, early investigations of VE demonstrated a decline in protection against symptomatic infection for adolescents aged 12-15 years and adults* (5). The PROTECT† prospective cohort of 1,364 children and adolescents aged 5-15 years was tested weekly for SARS-CoV-2, irrespective of symptoms, and upon COVID-19-associated illness during July 25, 2021-February 12, 2022. Among unvaccinated participants (i.e., those who had received no COVID-19 vaccine doses) with any laboratory-confirmed SARS-CoV-2 infection, those with B.1.617.2 (Delta) variant infections were more likely to report COVID-19 symptoms (66%) than were those with Omicron infections (49%). Among fully vaccinated children aged 5-11 years, VE against any symptomatic and asymptomatic Omicron infection 14-82 days (the longest interval after dose 2 in this age group) after receipt of dose 2 of the Pfizer-BioNTech vaccine was 31% (95% CI = 9%-48%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. Among adolescents aged 12-15 years, adjusted VE 14-149 days after dose 2 was 87% (95% CI = 49%-97%) against symptomatic and asymptomatic Delta infection and 59% (95% CI = 22%-79%) against Omicron infection. Fully vaccinated participants with Omicron infection spent an average of one half day less sick in bed than did unvaccinated participants with Omicron infection. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.
引用
- Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35298453. doi:10.15585/mmwr.mm7111e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。